Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Ludwig

Showing results (421-430 of 500) with videos related to

Pageof 50
Sort By:
Magnetic Resonance in Medicine|November 24, 2023
Changes in tissue sodium concentration and sodium relaxation times during the maturation of human knee cartilage: Ex vivo <sup>23</sup> Na MRI study at 10.5 TŠtefan Zbýň, Kai D Ludwig, Lauren E Watkins, et al.
Leukemia|September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)C Buske, E Hoster, M Dreyling, et al.
EJNMMI Research|April 27, 2023
Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinomaKevin P Labadie, Adrienne L Lehnert, Aimee L Kenoyer, et al.
Leukemia|December 17, 2009
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000A Möricke, M Zimmermann, A Reiter, et al.
Cell Chemical Biology|April 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Cell Chemical Biology|March 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Leukemia|January 9, 2004
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotypeN L Ramakers-van Woerden, H B Beverloo, A J P Veerman, et al.
Blood|September 10, 1998
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89W D Ludwig, H Rieder, C R Bartram, et al.
Scientific Reports|February 13, 2021
Glypican-3 targeted delivery of <sup>89</sup>Zr and <sup>90</sup>Y as a theranostic radionuclide platform for hepatocellular carcinomaKevin P Labadie, Andrew D Ludwig, Adrienne L Lehnert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2021
Glypican-3-Targeted <sup>227</sup>Th <b>α</b>-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular CarcinomaKevin P Labadie, Donald K Hamlin, Aimee Kenoyer, et al.
Pageof 50

Showing results (421-430 of 500) with videos related to

Sort By:
Pageof 50
Magnetic Resonance in Medicine|November 24, 2023
Changes in tissue sodium concentration and sodium relaxation times during the maturation of human knee cartilage: Ex vivo <sup>23</sup> Na MRI study at 10.5 TŠtefan Zbýň, Kai D Ludwig, Lauren E Watkins, et al.
Leukemia|September 27, 2008
The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)C Buske, E Hoster, M Dreyling, et al.
EJNMMI Research|April 27, 2023
Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinomaKevin P Labadie, Adrienne L Lehnert, Aimee L Kenoyer, et al.
Leukemia|December 17, 2009
Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000A Möricke, M Zimmermann, A Reiter, et al.
Cell Chemical Biology|April 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Cell Chemical Biology|March 28, 2024
Multiparatopic antibodies induce targeted downregulation of programmed death-ligand 1Seth D Ludwig, Bunyarit Meksiriporn, Jiacheng Tan, et al.
Leukemia|January 9, 2004
In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotypeN L Ramakers-van Woerden, H B Beverloo, A J P Veerman, et al.
Blood|September 10, 1998
Immunophenotypic and genotypic features, clinical characteristics, and treatment outcome of adult pro-B acute lymphoblastic leukemia: results of the German multicenter trials GMALL 03/87 and 04/89W D Ludwig, H Rieder, C R Bartram, et al.
Scientific Reports|February 13, 2021
Glypican-3 targeted delivery of <sup>89</sup>Zr and <sup>90</sup>Y as a theranostic radionuclide platform for hepatocellular carcinomaKevin P Labadie, Andrew D Ludwig, Adrienne L Lehnert, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 13, 2021
Glypican-3-Targeted <sup>227</sup>Th <b>α</b>-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular CarcinomaKevin P Labadie, Donald K Hamlin, Aimee Kenoyer, et al.
Pageof 50